{
    "clinical_study": {
        "@rank": "35217", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "recombinant human endostatin"
            }
        ], 
        "brief_summary": {
            "textblock": "Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung\n      cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial\n      growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of\n      pleural fluid. The other widely used treatment for MPE is recombinant human endostatin."
        }, 
        "brief_title": "Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Pleural Effusion", 
                "Pleural Effusion, Malignant"
            ]
        }, 
        "detailed_description": {
            "textblock": "We designed this clinical trial to determine the efficacy and Safety of intrapleural\n      Bevacizumab versus recombinant human endostatin as a treatment for malignant pleural\n      effusions (MPE) in patients with non-small cell lung cancer (NSCLC)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient who was confirmed stage IV NSCLC with malignant pleural effusion confirmed by\n        cytology.\n\n        Males or females aged \u226518 years, < 75 years. Eastern Cooperative Oncology Group (ECOG)\n        performance status 0-3. Life expectancy \u226512 weeks. Ability to maintain a drainage\n        catheter. Previous intrapleural administration of chemotherapeutic drugs (preferred\n        bleomycin) Males and females should be contraceptive during the period of the trial until\n        8 weeks after the last administration of the drug.\n\n        Adequate bone marrow, renal, and liver function are required. Able to comply with the\n        required protocol and follow-up procedures, and able to receive oral medications.\n\n        Institutional review board-approved informed consent will be obtained for every patient\n        before initiation of any trial-specific procedure or treatment.\n\n        Exclusion Criteria:\n\n        Any unstable systemic disease (including active infection, uncontrolled hypertension,\n        unstable angina, congestive heart failure, myocardial infarction within the previous year,\n        serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n\n        Active thoracic cavity or systemic bleeding. Major surgical procedure, open biopsy, or\n        significant traumatic injury within 28 days prior to day 0.\n\n        Female subjects should not be pregnant or breast-feeding. Known sensitivity to Bevacizumab\n        or Endostar. Patients must not be on therapeutic anticoagulation with warfarin, heparin or\n        low molecular weight heparin.\n\n        Adequate hematological function: Absolute neutrophil count (ANC) \u22651.5 x 109/L, and\n        Platelet count \u2265100 x 109/L.\n\n        Adequate renal function: Serum creatinine \u2264 1.5 x ULN, or \u2265 50 ml/min. Adequate liver\n        function :Total bilirubin \u00a3 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase\n        (ALT) and Aspartate Aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases,\n        or < 5 x ULN in case of liver metastases.\n\n        Patient assessed by the investigator to be unable or unwilling to comply with the\n        requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005120", 
            "org_study_id": "ZhejiangUniv"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Intrapleural administration of bevacizumab", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Intrapleural administration of recombinant human endostatin", 
                "intervention_name": "recombinant human endostatin", 
                "intervention_type": "Drug", 
                "other_name": "Endostar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Endostatins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "doczq.2008@gmail.com", 
                    "last_name": "Qiong Zhao, PhD", 
                    "phone": "0571-87236802"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "The first affiliated hospital, Zhejiang University"
                }, 
                "investigator": {
                    "last_name": "Qiong Zhao, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "doczq.2008@gmail.com", 
                    "last_name": "Qiong Zhao, PhD", 
                    "phone": "0571-87236802"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "Qiong Zhao"
                }, 
                "investigator": {
                    "last_name": "Qiong Zhao, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC)", 
        "other_outcome": {
            "measure": "Quality of life", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "doczq.2008@gmail.com", 
            "last_name": "Qiong Zhao, PhD", 
            "phone": "0571-87236802"
        }, 
        "overall_official": {
            "affiliation": "The first affiliated hospital, Zhejiang University", 
            "last_name": "Qiong Zhao, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005120"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}